uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone31-20-240-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.28 million
Profitability
Miscellaneous
Employees212
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Uniqure (NASDAQ:QURE) Frequently Asked Questions
What is Uniqure's stock symbol?
Uniqure trades on the NASDAQ under the ticker symbol "QURE."
How were Uniqure's earnings last quarter?
Uniqure NV (NASDAQ:QURE) issued its earnings results on Monday, April, 29th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.71) by $0.03. The biotechnology company earned $1.14 million during the quarter, compared to analysts' expectations of $2 million. Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%. View Uniqure's Earnings History.
When is Uniqure's next earnings date?
What price target have analysts set for QURE?
12 Wall Street analysts have issued 1-year price objectives for Uniqure's stock. Their predictions range from $35.00 to $100.00. On average, they expect Uniqure's share price to reach $76.80 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View Analyst Price Targets for Uniqure.
What is the consensus analysts' recommendation for Uniqure?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Uniqure.
What are Wall Street analysts saying about Uniqure stock?
Here are some recent quotes from research analysts about Uniqure stock:
- 1. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and $81 PT on uniQure. This morning, Spark (Neutral) filed a 14D-9, which detailed a timeline (Figure 1) of potential partnership and acquisition talks the company had. Our key takeaway is that four parties, including Roche (RHHBY – NC) were in discussions regarding a co- development and co-promotion partnership relating to hemophilia A. Three of these parties (including Roche) were involved in acquisition talks. This detailed process indicates there is an immense interest in hemophilia gene therapy programs from pharma." (3/7/2019)
- 2. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (3/6/2019)
- 3. HC Wainwright analysts commented, "Our $73 price target, is based on a 13-year DCF analysis that incorporates rNPV of two clinical-stage pipeline products AMT-061 and AMT-130. For AMT-061, we assume a 70% POS driven by the compelling clinical updates and single- arm Phase 3 involving about 50 patients, along with RMAT and PRIME designations. We anticipate commercial launch during 2H21, with a NAB-based exclusion of 5%, and model risk-adjusted peak sales of roughly $765M, during 2028. We assume a launch price of $850K, which could be an underestimate based on the 7 plus years of anticipated durability." (2/26/2019)
- 4. Chardan Capital analysts commented, "We note organ-specific promoters will help mitigate toxicity issues associated with off-target expression of transgenes. In addition, better promoters means potentially lower dosage of vector genomes will be required to achieve therapeutic levels of therapeutic protein levels." (10/18/2018)
Has Uniqure been receiving favorable news coverage?
Press coverage about QURE stock has been trending somewhat positive on Friday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Uniqure earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Uniqure's key competitors?
Some companies that are related to Uniqure include Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO), Marina Biotech (MRNA), Catalent (CTLT), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Array Biopharma (ARRY), Nektar Therapeutics (NKTR) and Amarin (AMRN).
What other stocks do shareholders of Uniqure own?
Who are Uniqure's key executives?
Uniqure's management team includes the folowing people:
- Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 47)
- Dr. Sander van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & GM of Amsterdam (Age 65)
- Mr. Jonathan Garen, Chief Bus. Officer (Age 53)
- Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
- Dr. Scott T. McMillan, Chief Operations Officer (Age 60)
Who are Uniqure's major shareholders?
Uniqure's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (9.76%), OppenheimerFunds Inc. (4.81%), Redmile Group LLC (3.46%), Federated Investors Inc. PA (3.37%), Macquarie Group Ltd. (1.80%) and BlackRock Inc. (1.20%). Company insiders that own Uniqure stock include Alexander Edward Kuta III, Christian Klemt, David Schaffer, Deventer Sander Van, Harald Petry, Jeremy P Springhorn, Maria E Cantor, Matthew C Kapusta, Philip Astley-Sparke, Scott T Mcmillan and Steven Zelenkofske. View Institutional Ownership Trends for Uniqure.
Which major investors are selling Uniqure stock?
QURE stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Eqis Capital Management Inc., BlackRock Inc., WS Management Lllp, Dynamic Technology Lab Private Ltd, Advisor Group Inc., Envestnet Asset Management Inc. and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold Uniqure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, David Schaffer, Deventer Sander Van, Jeremy P Springhorn, Matthew C Kapusta, Philip Astley-Sparke, Scott T Mcmillan and Steven Zelenkofske. View Insider Buying and Selling for Uniqure.
Which major investors are buying Uniqure stock?
QURE stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Vivo Capital LLC, OppenheimerFunds Inc., Macquarie Group Ltd., FIL Ltd, Renaissance Technologies LLC, Graticule Asia Macro Advisors LLC and Trexquant Investment LP. View Insider Buying and Selling for Uniqure.
How do I buy shares of Uniqure?
Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uniqure's stock price today?
One share of QURE stock can currently be purchased for approximately $64.25.
How big of a company is Uniqure?
Uniqure has a market capitalization of $2.43 billion and generates $11.28 million in revenue each year. The biotechnology company earns $-83,300,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Uniqure employs 212 workers across the globe.
What is Uniqure's official website?
How can I contact Uniqure?
Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected]
MarketBeat Community Rating for Uniqure (NASDAQ QURE)
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
